The downgrade from JP Morgan, a major financial institution, could negatively impact investor sentiment towards Lyell Immunopharma. The significant reduction in the price target from $15 to $5 suggests that the analyst sees less potential for the stock's growth, which could lead to a sell-off in the short term.